Newswise — Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Psychiatric Association Annual Meeting in New Orleans, May 22 to 26. Among the most significant presentations are the following:
•Is there a better way for doctors to learn about the comparative effectiveness of psychiatric medications?
Dr. Jeffrey A. LiebermanPsychiatrist-in-chief at NewYork-Presbyterian Hospital/Columbia University Medical Center, Lawrence E. Kolb Professor and chairman of psychiatry at Columbia University College of Physicians and Surgeons, and director of the New York State Psychiatric Institute
Dr. Jeffrey A. Lieberman is chairing a symposium on the question of how clinical trials can provide information on the comparative effectiveness of approved treatments for major mental disorders in order to guide clinicians in treatment recommendations. Currently, the lack of this information leaves clinicians unable to make rational evidence-based treatment decisions. The majority of research comparing treatments is sponsored by the pharmaceutical industry, usually in the context of traditional randomized controlled trial designs. Another approach is practical clinical trials, which address real world questions relevant to clinicians and policy makers. The federal government has prioritized funding comparative effectiveness research to provide clinicians and policy makers with this vital information. This symposium brings together the leading comparative effectiveness researchers in the U.S. and the U.K. Each will present on the studies of treatments for the disorder in which they specialize.
Monday, May 24, 9 a.m. – Noon
•Early detection and intervention in schizophrenia: an idea whose time has come
Dr. Jeffrey A. LiebermanPsychiatrist-in-chief at NewYork-Presbyterian Hospital/Columbia University Medical Center, Lawrence E. Kolb Professor and chairman of psychiatry at Columbia University College of Physicians and Surgeons, and director of the New York State Psychiatric Institute
Dr. Jeffrey A. Lieberman is chairing a symposium on early detection and intervention in schizophrenia. In recent years the prospect of early detection and intervention to forestall the onset or limit complications and disability associated with schizophrenia has taken hold and generated great enthusiasm. Although much remains to be done to develop the methodology and evidence for effective intervention strategies, initial results of studies show considerable promise for this strategy. This symposium will focus on presenting the most recent results of key projects that have been conducted to evaluate the effects of early detection and intervention strategies. Each speaker will comment on work in their particular area of interest and present the results of their most current studies. Dr. Lieberman will present on early detection and intervention in psychotic disorders. He will describe studies attempting to develop biological measures to aid in the diagnosis of patients with the first phase of schizophrenia or who are at high risk for developing schizophrenia or related psychotic disorders. Promising lines of investigation include studies using MRI and PET neuroimaging to access pathophysiological processes indicative of an incipient psychotic disorder.
Monday, May 24, 2 p.m. – 5 p.m.
•Latest Research on Brain Stimulation Techniques for Depression
Dr. Sarah LisanbyChief of the Brain Stimulation and Therapeutic Modulation Division at Columbia Psychiatry and the NYS Psychiatric Institute and a psychiatrist at NewYork-Presbyterian Hospital/Columbia University Medical Center
Dr. Sarah Lisanby will present findings of the most recent NIMH-funded study of transcranial magnetic stimulation (TMS), which was recently approved by the FDA for major depressive disorder. The non-invasive treatment stimulates the brain with a pulsing electromagnet. She will also present ongoing research comparing magnetic seizure therapy (MST) with electroconvulsive therapy (ECT). Dr. Lisanby and colleagues are investigating MST as an alternative to ECT with potentially reduced side effects.
Monday, May 24, 2 p.m. – 5 p.m. (Update on Magnetic Seizure Therapy)Tuesday, May 25, 9 a.m. – Noon (APA Task Force Report on Electroconvulsive Therapy)Tuesday, May 25, 2 p.m. – 5 p.m. (Treatment of Depression with Transcranial Magnetic Stimulation)
•Psychiatry in the Age of FacebookDr. Deborah Cabaniss A psychotherapist at NewYork-Presbyterian Hospital/Columbia University Medical Center and clinical professor of psychiatry at Columbia University College of Physicians and Surgeons
Dr. Cabaniss will present on the use of the Internet in psychiatry. Titled "If a Patient Googles Me, What Will They Find? -- The Information Age and Its Impact on Residency," her presentation will outline guidelines for residents on keeping the personal and professional separate, including by ensuring adequate privacy settings in Facebook. She notes that while many patients may feel more comfortable using e-mail or other Internet tools, they aren’t completely secure and talking is central to psychotherapy. The presentation will be made along with colleagues in the Group for the Advancement of Psychiatry Medical Education Committee, of which Dr. Cabaniss is a member.
Monday, May 24, 9 a.m. – 10:30 a.m.
Office of Public AffairsNewYork-Presbyterian Hospital/Columbia University Medical Center627 West 165th StreetNew York, NY 10032
tel: 212.305.5587fax: 212.305.8023email: [email protected]
RSS